 TEL AVIV, Israel, May 3, 2021 PRNewswire -- Galmed Pharmaceuticals Ltd. Nasdaq: GLMD Galmed or the Company, a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the National Medical Products Administration NMPA has granted approval for the Investigational New Drug IND application for Galmeds Phase 3 ARMOR registrational study of Aramchol for the treatment of NASH Fibrosis. 